Article Text

Download PDFPDF
Early use of mineralocorticoid receptor antagonists in ST-elevation myocardial infarction: is it ever too early?

Statistics from Altmetric.com

Footnotes

  • Contributors Both authors drafted the manuscript and revised it.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests PSJ has received consulting fees from Novartis and Vifor Pharma, advisory board and speaker’s fees from Novartis and grant funding from Boheringer Ingelheim.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles